• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Nxera Pharma (TSE:4565) Stock Confronts Profit Reversal After Quarterly Loss

    Simply Wall St·08/09/2026 00:25:27
    Listen to the news

    Investors came into Nxera Pharma’s Q2 2026 report already bruised, with the stock down about 26% over the past three months and trading at ¥865 at the last close. The long term pitch has been a high growth drug platform that eventually turns profitable. The latest quarter instead put the profit squeeze front and center. Revenue printed at ¥7,654m, yet the company swung from a ¥1,793m profit in Q1 to a ¥202m loss, and basic earnings per share moved from ¥19.81 to a loss of ¥2.22.

    Is Nxera Pharma now a mispriced growth story or just an expensive way to own mounting losses? Compare the market’s view with a full valuation cross check in the valuation analysis for Nxera Pharma.

    Q2 2026 Earnings Summary

    • Revenue (Q2 2026 vs. Q2 2025): ¥7,654m vs. ¥8,450m (declined 9.4%)
    • Net Income or Loss (Q2 2026 vs. Q2 2025): loss of ¥202m vs. loss of ¥2,377m (loss narrowed 91.5%)
    • Basic EPS (Q2 2026 vs. Q2 2025): loss of ¥2.22 per share vs. loss of ¥26.35 per share (loss per share narrowed 91.6%)
    • Trailing 12 Month Net Income or Loss (TTM to Q2 2026 vs. TTM to Q2 2025): loss of ¥7,802m vs. loss of ¥3,272m (loss widened 2.4x)

    Prefer clean charts instead of scrolling through pages of earnings figures and ratios? See Nxera Pharma’s full financial picture at a glance, including a visual breakdown of its recent earnings and profitability trends, in the company report for Nxera Pharma.

    TSE:4565 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026
    TSE:4565 Trailing 12-Month Revenue & Expenses Breakdown as at Aug 2026

    Nxera Pharma bull story leans on improving earnings mix

    The bullish angle on Nxera Pharma rests on the idea that its platform and partnerships can turn science into recurring cash flows. Recent figures give some support. H1 FY2026 revenue reached ¥18.9b and shifted from an operating loss last year to an IFRS operating profit of ¥1.9b. Losses in the latest quarter also narrowed sharply year on year. Platform milestones rose from ¥5b to ¥8b, which shows paying partners are progressing programs. Both commercial drugs and the platform are profitable on a core basis, which fits a move from pure investment toward delivery.

    Bear case focuses on volatility and cumulative losses

    The bear argument for Nxera Pharma centers on earnings volatility and ongoing burn. Q2 FY2026 revenue declined 9.4% year on year to ¥7,654m and the company moved from a ¥1,793m profit in Q1 to a ¥202m loss. Trailing 12 month losses widened to ¥7,802m from ¥3,272m. The stock is down about 26% over three months, which shows investors reacting to this pressure. Even with H1 turning an operating profit, the step back in Q2 and the larger cumulative loss keep concerns about cost intensity and funding needs firmly on the table.

    Compare Nxera Pharma’s shift to core profitability and narrowing quarterly losses with how institutional analysts are framing the risk reward. See the consensus price target analysis for Nxera Pharma to check whether the recent share price slide has pulled the stock closer to or further away from where the street thinks it should trade.

    Take Control Of Your Next Move

    If Nxera Pharma’s swing from profit in Q1 to a loss in Q2 has your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the earnings story develops. After you own it or any other stock, keep a clear view of your positions with the Portfolio Command Center that cuts through noise and focuses on the updates that matter most. For a longer term plan, tap into crowd wisdom and compare your thesis with thousands of other investors inside the Community. Spot potential catalysts and risks earlier so you can stay a step ahead of the market and make more confident decisions.

    Seeking Alternatives Beyond Nxera Pharma?

    Fresh ideas move quickly. Some stocks build breakout momentum, others get caught dropping before the crowd even notices. Check these curated shortlists while it matters and get in early.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.